230 related articles for article (PubMed ID: 21953143)
1. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.
Monach PA; Tomasson G; Specks U; Stone JH; Cuthbertson D; Krischer J; Ding L; Fervenza FC; Fessler BJ; Hoffman GS; Ikle D; Kallenberg CG; Langford CA; Mueller M; Seo P; St Clair EW; Spiera R; Tchao N; Ytterberg SR; Gu YZ; Snyder RD; Merkel PA
Arthritis Rheum; 2011 Dec; 63(12):3988-97. PubMed ID: 21953143
[TBL] [Abstract][Full Text] [Related]
2. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.
Monach PA; Warner RL; Tomasson G; Specks U; Stone JH; Ding L; Fervenza FC; Fessler BJ; Hoffman GS; Iklé D; Kallenberg CG; Krischer J; Langford CA; Mueller M; Seo P; St Clair EW; Spiera R; Tchao N; Ytterberg SR; Johnson KJ; Merkel PA
Ann Rheum Dis; 2013 Aug; 72(8):1342-50. PubMed ID: 22975753
[TBL] [Abstract][Full Text] [Related]
3. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
4. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R; Ljevak M; Vikgren J; Bokarewa M
Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
[TBL] [Abstract][Full Text] [Related]
5. The significance of metalloproteinase 3 (MMP-3), chemokine CXC ligand 13 (CXCL-13) and complement component C5a in different stages of ANCA associated vasculitis.
Rymarz A; Mosakowska M; Niemczyk S
Sci Rep; 2021 Mar; 11(1):5132. PubMed ID: 33664330
[TBL] [Abstract][Full Text] [Related]
6. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis.
Ishizaki J; Takemori A; Suemori K; Matsumoto T; Akita Y; Sada KE; Yuzawa Y; Amano K; Takasaki Y; Harigai M; Arimura Y; Makino H; Yasukawa M; Takemori N; Hasegawa H;
Arthritis Res Ther; 2017 Sep; 19(1):218. PubMed ID: 28962592
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
8. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV).
Schneeweis C; Rafalowicz M; Feist E; Buttgereit F; Rudolph PE; Burmester GR; Egerer K
Clin Exp Rheumatol; 2010; 28(1 Suppl 57):62-6. PubMed ID: 20412705
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides.
Boehme MW; Schmitt WH; Youinou P; Stremmel WR; Gross WL
Am J Med; 1996 Oct; 101(4):387-94. PubMed ID: 8873509
[TBL] [Abstract][Full Text] [Related]
11. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.
Md Yusof MY; Vital EM; Das S; Dass S; Arumugakani G; Savic S; Rawstron AC; Emery P
Ann Rheum Dis; 2015 Sep; 74(9):1734-8. PubMed ID: 25854586
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of low erythrocyte sedimentation rate/high C-reactive protein to antineutrophil cytoplasmic antibody-associated vasculitis.
Park PG; Song JJ; Park YB; Lee SW
J Clin Lab Anal; 2022 Feb; 36(2):e24237. PubMed ID: 34997790
[TBL] [Abstract][Full Text] [Related]
13. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
14. Platelet to lymphocyte ratio is associated with the current activity of ANCA-associated vasculitis at diagnosis: a retrospective monocentric study.
Park HJ; Jung SM; Song JJ; Park YB; Lee SW
Rheumatol Int; 2018 Oct; 38(10):1865-1871. PubMed ID: 30088046
[TBL] [Abstract][Full Text] [Related]
15. Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.
Monach PA; Kümpers P; Lukasz A; Tomasson G; Specks U; Stone JH; Cuthbertson D; Krischer J; Carette S; Ding L; Hoffman GS; Iklé D; Kallenberg CG; Khalidi NA; Langford CA; Seo P; St Clair EW; Spiera R; Tchao N; Ytterberg SR; Haubitz M; Merkel PA
PLoS One; 2012; 7(1):e30197. PubMed ID: 22279570
[TBL] [Abstract][Full Text] [Related]
16. Serum Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein-1 Can Predict Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Pilot Monocentric Study.
Ahn SS; Kim JO; Yoon T; Song JJ; Park YB; Lee SW; Park SG
Biomed Res Int; 2019; 2019():7508240. PubMed ID: 31236412
[TBL] [Abstract][Full Text] [Related]
17. Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Miloslavsky EM; Cascino M; Unizony SH; Lu N; Hoffman GS; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera R; St Clair EW; Specks U; Brunetta P; Choi HK; Stone JH
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1004-1010. PubMed ID: 27696762
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
